SELLAS Life Sciences Group (SLS) Competitors $1.91 +0.15 (+8.52%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.52%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. DNTH, GHRS, MRVI, TBPH, UPXI, MGTX, ABUS, KALV, KURA, and BCAXShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Dianthus Therapeutics (DNTH), GH Research (GHRS), Maravai LifeSciences (MRVI), Theravance Biopharma (TBPH), Upexi (UPXI), MeiraGTx (MGTX), Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors Dianthus Therapeutics GH Research Maravai LifeSciences Theravance Biopharma Upexi MeiraGTx Arbutus Biopharma KalVista Pharmaceuticals Kura Oncology Bicara Therapeutics SELLAS Life Sciences Group (NASDAQ:SLS) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Do analysts rate SLS or DNTH? SELLAS Life Sciences Group presently has a consensus price target of $7.00, suggesting a potential upside of 266.49%. Dianthus Therapeutics has a consensus price target of $54.00, suggesting a potential upside of 122.22%. Given SELLAS Life Sciences Group's higher possible upside, equities analysts plainly believe SELLAS Life Sciences Group is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLS or DNTH more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -132.51% -92.79% Dianthus Therapeutics -2,364.56%-34.72%-32.72% Do institutionals and insiders have more ownership in SLS or DNTH? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, SLS or DNTH? SELLAS Life Sciences Group has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences GroupN/AN/A-$30.88M-$0.32-5.97Dianthus Therapeutics$6.24M125.36-$84.97M-$3.25-7.48 Which has more risk and volatility, SLS or DNTH? SELLAS Life Sciences Group has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Does the media refer more to SLS or DNTH? In the previous week, Dianthus Therapeutics had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Dianthus Therapeutics and 4 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.81 beat Dianthus Therapeutics' score of -0.14 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySELLAS Life Sciences Group and Dianthus Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.12M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-5.9721.2831.3026.05Price / SalesN/A345.81432.98193.75Price / CashN/A43.1937.7358.48Price / Book7.648.129.536.61Net Income-$30.88M-$54.72M$3.26B$265.65M7 Day Performance17.18%2.62%2.13%2.02%1 Month Performance3.80%2.68%2.80%-0.31%1 Year Performance44.70%10.93%30.68%19.06% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group2.8749 of 5 stars$1.91+8.5%$7.00+266.5%+45.8%$201.12MN/A-5.9710DNTHDianthus Therapeutics1.0549 of 5 stars$20.96+1.1%$53.00+152.9%-12.0%$667.59M$6.24M-6.4580Analyst ForecastAnalyst RevisionHigh Trading VolumeGHRSGH Research2.7027 of 5 stars$12.67-0.9%$32.00+152.6%+17.7%$665.44MN/A-17.1210Positive NewsMRVIMaravai LifeSciences4.0349 of 5 stars$2.57-1.5%$5.75+123.7%-72.3%$664.66M$259.18M-1.89610Positive NewsOptions VolumeTBPHTheravance Biopharma2.1203 of 5 stars$13.61+3.5%$21.33+56.7%+73.7%$662.25M$64.38M56.71110High Trading VolumeUPXIUpexi2.7689 of 5 stars$6.92-5.9%$15.50+124.0%+107.5%$656.81M$26M0.00130MGTXMeiraGTx4.4917 of 5 stars$7.97-2.4%$24.00+201.1%+89.6%$656.59M$33.28M-3.91300ABUSArbutus Biopharma2.736 of 5 stars$3.38+0.3%$5.50+62.7%-5.8%$645.07M$6.17M-11.6690News CoverageKALVKalVista Pharmaceuticals4.0138 of 5 stars$13.34+3.6%$26.29+97.0%+8.0%$643.40MN/A-3.62100KURAKura Oncology3.9439 of 5 stars$7.48+1.9%$24.10+222.2%-61.2%$637.09M$53.88M-3.31130BCAXBicara Therapeutics1.6238 of 5 stars$11.47-1.5%$31.86+177.8%N/A$635.11MN/A-3.6232Analyst Forecast Related Companies and Tools Related Companies Dianthus Therapeutics Alternatives GH Research Alternatives Maravai LifeSciences Alternatives Theravance Biopharma Alternatives Upexi Alternatives MeiraGTx Alternatives Arbutus Biopharma Alternatives KalVista Pharmaceuticals Alternatives Kura Oncology Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access